Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is used primarily to treat obsessive-compulsive disorder, although in some countries it is also approved to treat depression. It also potently inhibits CYP1A2 and CYP2C19, moderately inhibits CYP2C9, CYP2D6 and CYP3A4. It is the only achiral clinically-used second-generation monoamine reuptake inhibitor (which is a generalized class including SSRIs, SNRIs, NRI, NDRI, etc.).
↑Hemeryck, A; Belpaire, FM (February 2002). "Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.". Current Drug Metabolism3 (1): 13–37. PMID11876575. doi:10.2174/1389200023338017.